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Abstract
 
HIV-1 naturally infects chimpanzees and humans, but does not infect Old World monkeys be-
cause of replication blocks that occur after virus entry into the cell. To understand the species-
specific restrictions operating on HIV-1 infection, the ability of HIV-1 to infect the cells of
New World monkeys was examined. Primary cells derived from common marmosets and
squirrel monkeys support every phase of HIV-1 replication with the exception of virus entry.
Efficient HIV-1 entry typically requires binding of the viral envelope glycoproteins and host
cell receptors, CD4 and either CCR5 or CXCR4 chemokine receptors. HIV-1 did not de-
tectably bind or utilize squirrel monkey CD4 for entry, and marmoset CD4 was also very in-
efficient compared with human CD4. A marmoset CD4 variant, in which residues 48 and 59
were altered to the amino acids found in human CD4, supported HIV-1 entry efficiently. The
CXCR4 molecules of both marmosets and squirrel monkeys supported HIV-1 infection, but
the CCR5 proteins of both species were only marginally functional. These results demonstrate
that the CD4 and CCR5 proteins of New World monkeys represent the major restriction
against HIV-1 replication in these primates. Directed adaptation of the HIV-1 envelope glyco-
proteins to common marmoset receptors might allow the development of New World monkey
models of HIV-1 infection.
Key words: human immunodeﬁciency virus • species restrictions • New World monkeys • 
receptors • virus entry
 
Introduction
 
The primate lentiviruses include the human immunodefi-
ciency viruses (HIV-1 and HIV-2) and simian immunode-
ficiency viruses (SIVs).
 
*
 
 In nature, HIV-1 and HIV-2 infect
humans, HIV-1–related CPZ viruses infect chimpanzees,
and SIV variants infect African monkeys (1–4). Humans in-
fected by HIV-1 and HIV-2 and Asian macaques infected
by certain SIV and HIV-2 strains often develop life-threat-
ening immunodeficiency (AIDS) due to depletion of CD4-
positive T lymphocytes (1, 2, 5–8). HIV-1 is the major
cause of the global AIDS epidemic (9).
Infection by primate immunodeficiency viruses is depen-
dent upon a number of host cell factors, some of which ex-
hibit species-specific variation. An appreciation of the
functional consequences of this variation for susceptibility
to virus infection is important for understanding the origins
and expansion of the HIV-1 epidemic. Furthermore, this
knowledge can expedite the development of animal models
of HIV-1 infection, which facilitate the design and im-
provement of therapeutic and prophylactic modalities and
further our understanding of pathogenesis.
Currently available animal models of HIV-1 infection
have limitations. HIV-1 infection of chimpanzees rarely re-
sults in immunodeficiency (10–15). Furthermore, the en-
dangered status of these animals limits their availability and
prohibits many experiments (16).
Asian rhesus macaques infected with certain strains of
SIV and HIV-2 develop fatal AIDS-like illness, and this
model has been useful in studying pathogenesis (17, 18).
However, for therapeutic and vaccine studies, differences
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; RT, reverse transcriptase; SHIV,
simian-HIV; SIV, simian immunodeficiency virus; SS, 
 
Saimiri sciureus
 
;
VSV, vesicular stomatitis virus. 
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between SIV and HIV-1 often preclude extrapolation of
results derived from this model to HIV-1–infected humans
(19). For example, many antiviral drugs and immune re-
sponses directed against HIV-1 do not cross-react with SIV
components. HIV-1 entry, which depends upon the bind-
ing of the viral gp120 envelope glycoprotein to host cell
receptors (CD4 [20–22] and one of the chemokine recep-
tors, CCR5 or CXC chemokine receptor [CXCR]4 [23–
29]), is efficient in Old World monkey cells (30, 31). These
cells, however, exhibit blocks to HIV-1 infection in an
early stage of virus infection after virus entry (32). Chi-
meric simian–HIVs (SHIVs) encoding the HIV-1 envelope
glycoproteins (and the HIV-1 Tat, Rev, and Vpu regula-
tory proteins) can infect and, in some cases, induce AIDS-
like illness in Old World monkeys (30, 33). The consis-
tency and rapidity of AIDS development in SHIV-infected
macaques have made this model extremely useful in studies
of viral pathogenesis and vaccine development. Nonethe-
less, because many antiviral agents and immune responses
are directed against HIV-1 elements not included in the
available SHIV chimerae, the development of new animal
models involving infection with more complete HIV-1–
like viruses is a worthy goal.
Mammalian species other than the primates have been
examined as possible hosts for HIV-1. Rabbits were re-
ported to be susceptible to HIV-1 infection, but the low
level and reproducibility of virus replication in this species
renders this model practically useless (34, 35). The poor
ability of rabbits and rodent species to support HIV-1 in-
fection has been investigated (36). The mouse and rabbit
CD4 and CCR5 molecules do not support efficient HIV-1
entry into host cells (24, 37–40). Although rabbit CXCR4
is not permissive for HIV-1 entry (38), some HIV-1 strains
can utilize murine CXCR4 (41, 42). Transgenic mice ex-
pressing human CD4 and coreceptor molecules fail to sup-
port HIV-1 replication even though virus entry occurs (43,
44). The identification of human cyclin T as a Tat cofactor
allowed proviral transcriptional blocks to be overcome in
mouse cells (45–48). Assembly defects exist for HIV-1 in
murine cells that further complicate the development of
small animal models of HIV-1 infection (49). Likewise, de-
spite some detectable level of HIV-1 replication in cultured
cells from CD4/CCR5 transgenic rabbits, in vivo replica-
tion of HIV-1 in this host was very limited (38, 50).
The existence of multiple blocks to HIV-1 infection in
mammals evolutionarily distant from humans prompted us
to investigate the nature of HIV-1 replication blocks in the
New World primates, which are more closely related to
the natural hosts of primate immunodeficiency viruses.
Some early reports (51, 52) suggested that the PBMCs of
some New World monkeys could support HIV-1 infec-
tion, although the validity of this claim is questionable; the
same group reported that rhesus macaque PBMCs, which
have been shown to exhibit stringent blocks to HIV-1 in-
fection (32), also allowed HIV-1 replication (51, 52). Intra-
peritoneal inoculation of HIV-1 into two New World
monkeys, cotton-top tamarins and common marmosets,
did not result in seroconversion (53). The basis for the ap-
parently minimal replication of HIV-1 in New World
monkeys is unknown. Previous studies suggested that re-
combinant HIV-1 vectors pseudotyped with the vesicular
stomatitis virus (VSV) G glycoprotein could infect and ex-
press a heterologous protein in New World, but not Old
World, monkey cells (32). Thus, at least some of the early
blocks to HIV-1 infection in Old World monkeys are not
present in New World monkeys. The ability of HIV-1 to
negotiate late stages of the retroviral life cycle in New
World monkey cells is unknown. Here we investigate the
basis for the restricted replication of HIV-1 in the cells of
two New World monkey species.
 
Materials and Methods
 
Cell Lines and Primary Cell Cultures.
 
293T and Cf2Th (Ameri-
can Type Culture Collection) cells were grown in DMEM-10%
FCS with antibiotics. Jurkat and CEMx174 human T cell lines
were cultured in RPMI 1640–10% FCS with antibiotics. Squirrel
monkey (
 
Saimiri sciureus
 
 or SS), common marmoset (
 
Callithrix jac-
chus
 
 or CJ), and rhesus macaque (
 
Macaca mulatta
 
 or MM) PBMCs
were isolated from fresh blood by Ficoll-Paque (Amersham Bio-
sciences) density centrifugation. These animals were maintained
in accordance with the guidelines of the Committee on Animals
for the Harvard Medical School and the Guide for Care and Use
of Laboratory Animals. All isolated primary cells were cultured
(10
 
6
 
 cells/ml) in RPMI 1640–10% FCS with antibiotics. Activa-
tion of primary cells was achieved by an initial 3-d stimulation
with 1 
 
 
 
g/ml purified phytohemagglutinin (Murex Biotech) and
subsequent culturing with 10 U/ml of recombinant human IL-2
(Collaborative Biomedical Products).
 
Virus Preparation.
 
Replication-competent HIV-1 virus was
generated by transfecting 10 
 
 
 
g pNL4–3 plasmid, which contains
an infectious HIV-1 NL4–3 provirus (54), into 5 
 
 
 
 10
 
6
 
 293T
cells using the calcium phosphate transfection method. VSV G-pseu-
dotyped  NL4–3 virus was generated by cotransfecting 10 
 
 
 
g
pNL4–3 and 2 
 
 
 
g of pHCMV-G (55, 56), a VSV G expression
plasmid. A recombinant HIV-1 capable of a single round of in-
fection and encoding the enhanced green fluorescent protein
(EGFP) was generated by cotransfecting 293T cells with 10 
 
 
 
g
pHIVec2.GFP (32), 10 
 
 
 
g pCMV
 
 
 
P1
 
 
 
envpA (55, 56), and 2
 
 
 
g of plasmids expressing viral envelope glycoproteins. These in-
cluded the pHCMV-G plasmid, which encodes the VSV G gly-
coprotein, and pSVIIIenv plasmids encoding the envelope glyco-
proteins derived from the HIV-1 strains HXBc2, 3.2, KB9, MN,
MCGP, ADA, JR-FL, and YU2 (57–59). 1 
 
 
 
g of a Rev-express-
ing plasmid was cotransfected in the case where the pHCMV-G
plasmid was used; this was not required when the pSVIIIenv plas-
mids, which encode functional HIV-1 Rev proteins, were used
(60). 12 h after transfection, the cells were washed and cultured in
fresh RPMI 1640–10% FCS with antibiotics. 24 h later, condi-
tioned medium containing recombinant viruses was harvested
and filtered (0.45-
 
 
 
m pore size). The level of recombinant virus
in the medium was determined using a previously described re-
verse transcriptase (RT) assay (61).
 
Virus Infections.
 
Approximately 100,000 RT cpm of NL4–3
or VSV G-pseudotyped NL4–3 virus were added to 5 
 
 
 
 10
 
5
 
 cells
in a total volume of 500 
 
 
 
l in 24-well plates. The target cells
were CEMx174 lymphocytes or primary MM, SS, or CJ PBMCs.
16 h after adding the virus to the cells, the plates were centri-
fuged at 2,000 rpm for 5 min. The medium was removed, and
the cells were washed with PBS and resuspended in 1.5 ml 
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RPMI-10% FCS supplemented with IL-2 and antibiotics. At 24 h
time points, 500-
 
 
 
l samples of the culture medium were col-
lected from duplicate cultures and used to measure RT activity.
Virus produced on day 2 after incubation of virus and cells was
collected, and equivalent amounts (5,000 cpm) of RT activity
were added to 5 
 
 
 
 10
 
5
 
 CEMx174 cells in a total volume of 1 ml
in 24-well plates. After incubation of the NL4–3 virus with pri-
mary MM, SS, or CJ PBMCs, no measurable virus was produced;
in this case, 1 ml of culture supernatant was added to the
CEMx174 cells. 1 d after infection the CEMx174 cells were
washed with PBS and resuspended in RPMI-10% FCS with
antibiotics. Subsequently, RT activity was measured in the
CEMx174 cell supernatants every 24 h.
 
Cloning of New World Monkey CD4 and Chemokine Receptor
cDNAs.
 
Messenger RNA was extracted from primary SS or CJ
PBMCs using the RNeasy Mini Kit (QIAGEN). After Dnase
treatment using the RNase-Free Dnase Set (QIAGEN), first-
strand cDNA was generated using the Reverse Transcription Sys-
tem (Promega). PCR was performed on 2 
 
 
 
l of the cDNA using
the Expand High Fidelity PCR System (Roche Diagnostic
Corp.). CXCR4 was amplified using primers CXCutr52:
GCTCCAGTAGCCACCGCATCT and CXCutr31: AAAACT-
GTACAATATTGGTCAGTC. CCR5 was amplified using
primers CC5utr53: GCTGAGACATCCGTTCCCCTAC and
CC5utr31: GCCCAGGCTGTGTATGAAAACT. CD4 was
amplified using primers CD4utr52: TCCCTCAGCAAGGCCA-
CAATG and CD4utr31: GATCTCCCTGGCCTCGTGC.
PCR products were sequenced using the same primers. Mole-
cules were cloned into the mammalian expression plasmid
pcDNA3.1(
 
 
 
) (Invitrogen). CD4 molecules were also cloned
into pcDNA3.1(
 
 
 
) ZEO(
 
 
 
) (Invitrogen). Predicted amino acid
sequence and alignments were generated using DNAstar software
(DNAstar, Inc.). Quick-change point mutations were made using
the following primers. For SS CD4 Y42S, 5
 
 
 
:AATATTCTGG-
GAGTTCAGAATTCCTTCGTGACTAGAGGTCAATCC and
3
 
 
 
:GGATTGACCTCTAGTCACGAAGGAATTCTGAACT-
CCCAGAATCTT. For SS CD4 Q48P, 5
 
 
 
:GCGATCGGT-
CAGCTTGGAGGGCCCTCTAGTCACGAAG and 3
 
 
 
:CTT-
CGTGACTAGAGGGCCCTCCAAGCTGACCGATCG. For
SS CD4 R33Q, 5
 
 
 
:GTTCCACTGGAAAACCTCCGACCA-
GATAAAGATTCTGGGAGTTCAGAAC and 3
 
 
 
:GTTCTGA-
ACTCCCAGAATCTTTATCTGGTCGGAGGTTTTCCAGT
GGAAC.
For CJ CD4 Q59R, 5
 
 
 
:CCAAGCTGGCCAATCGCATTG-
ACTGATCGTCTTGGGACCGAGGATCC and 3
 
 
 
:GGATC-
CTCGGTCCCAAGACGATCGCTTTGAGTCAATGCGATT-
GGCCAGCTTGG. For CJ CD4 Q48P, 5
 
 
 
:GCGATTGGC-
CAGCTTGGAGGGCCCTTTAGTCACGAAGGAG and 3
 
 
 
:
CTCCTTCGTGACTAAAGGGCCCTCCAAGCTGGCCAA-
TCGC.
 
Generation of Cell Lines Stably Expressing Receptors.
 
Cf2Th
cells were transfected with pcDNA 3.1 (
 
 
 
) plasmids express-
ing human, squirrel monkey or common marmoset CCR5 or
CXCR4 proteins. Clones were selected in DMEM-10% FCS
supplemented with 500 
 
 
 
g/ml G418 (GIBCO BRL). FACS
 
®
 
was used to enrich for cells expressing high levels of the re-
ceptors. These were then transfected with pcDNA3.1 ZEO
plasmids expressing the CD4 molecule derived from the
same species. Cells expressing the CD4 molecule and che-
mokine receptor were selected in medium containing 500
 
 
 
g/ml G418 and 300 
 
 
 
g/ml Zeocin (Invitrogen) and FACS
 
®
 
was used to identify cells expressing high levels of both re-
ceptors.
 
Monoclonal Antibody Recognition of Receptor Molecules.
 
Using
the calcium phosphate transfection method, 5 
 
 
 
 10
 
6
 
 Cf2Th cells
were transfected with 10 
 
 
 
g of plasmid expressing the CD4 or
chemokine receptor. After 48 h, the cells were detached with 5
mM EDTA in PBS, pelleted, washed, and resuspended in 95 
 
 
 
l
PBS containing 2% FCS and 5 
 
 
 
l of monoclonal antibody (final
antibody concentration was 10 nM). The monoclonal antibodies
(and the target proteins) were: 12G5 (CXCR4), 3A9 (CCR5),
2D7 (CCR5), CD4v4 (CD4) (BD Biosciences), OKT4A (CD4;
Ortho Diagnostic Systems), Q4120 (CD4; Sigma-Aldrich), and
44717.111 (CXCR4; R&D Systems). Samples were incubated
for 20 min at 4
 
 
 
C, washed, and analyzed by flow cytometry
(FACScan™; Becton Dickinson).
 
Virus Infection Assays.
 
Using the calcium phosphate transfec-
tion method, 5 
 
 
 
 10
 
6
 
 Cf2Th cells were transfected with 8 
 
 
 
g of
plasmids encoding receptors. After 16 h, the cells were washed
and plated at a density of 2.5 
 
 
 
 10
 
4
 
 cells per well in 24-well
plates. Untransfected cells were plated in parallel to provide neg-
ative controls. After 24 h, one well of cells from each experi-
mental group was stained with antibodies to assess the level of re-
ceptor expression on the cell surface. To each of the duplicate
remaining wells in the experimental group, 5 
 
 
 
 10
 
5
 
 RT cpm of
recombinant HIV-1 encoding EGFP was added in a total vol-
ume of 400 
 
 
 
l. Viruses contained various HIV-1 envelope gly-
coproteins or the VSV G glycoprotein, as discussed above. The
cultures were spinoculated by centrifuging the 24-well plates at
1,200 rpm for 45 min at room temperature (62). 48 h later, the
cells were harvested using 5 mM EDTA in PBS, fixed in 3.7%
formaldehyde (Sigma-Aldrich), and analyzed by flow cytometry
for EGFP expression.
Single-round infection assays with target cells stably expressing
receptors were conducted similarly, except that 5 
 
 
 
 10
 
5
 
 RT cpm
of recombinant virus was spinoculated onto 4 
 
 
 
 10
 
4
 
 cells per well
in 24-well plates. EGFP-positive cells were photographed with a
Nikon Eclipse TE 300 microscope and Roper Scientific CCD
camera before cell harvesting.
 
HIV-1 gp120-CD4 Binding Assays.
 
The HIV-1 gp120 gly-
coproteins from the R5 isolates ADA, YU2 and JR-FL were
produced by pSVIIIenv plasmids in which stop codons had been
introduced near the sequences encoding the natural gp120-gp41
junction. The plasmids were transfected into 293T cells using
the Geneporter 2 transfection reagent (Gene Therapy Systems)
and the medium harvested 48 h after transfection. The gp120
glycoproteins were purified by affinity chromatography using an
F105 antibody column and quantified by silver staining and
spectrophotometry.
To create target cells for the binding assays, 293T cells were
transfected with plasmids encoding CD4 variants using Gene-
porter 2 reagent. The CD4 molecules used were human CD4,
marmoset (CJ) CD4 proteins (wild-type and Q48P, Q59R, and
Q48P/Q59R), and squirrel monkey (SS) CD4 proteins (wild-
type and Q48P, Y42S, and Q48P/Y42S). Cells transiently ex-
pressing the CD4 variants were stained with the anti-CD4 anti-
body (Q4120; Sigma-Aldrich) to assess relative levels of surface
CD4 expression. Parallel samples of transiently transfected cells
were harvested with PBS/5 mM EDTA and resuspended in
PBS/2% FCS at a density of 4 
 
 
 
 10
 
7
 
 cells/ml. Then 2 
 
 
 
 10
 
6
 
cells were added to microcentrifuge tubes (Eppendorf) contain-
ing varying concentrations (0.01 nM to 3 
 
 
 
M) of the ADA,
YU2, and JR-FL gp120 glycoproteins. After a 1-h incubation at
37
 
 
 
C, cells were washed in PBS/2% FCS and resuspended in 100
 
 
 
l of PBS/2% FCS containing 1 
 
 
 
g of the C11 anti-gp120 anti-
body. After a 45-min incubation at 4
 
 
 
C, the cells were washed 
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once in PBS/2% FCS and resuspended in buffer containing 5 
 
 
 
l
of anti–human IgG-PE (Jackson ImmunoResearch Laboratories).
The cells were incubated for 20 min at 4
 
 
 
C, washed twice, and
analyzed using a Becton Dickinson FACScan™ using CELLQuest™
software.
 
Results
 
Susceptibility of New World Monkey PBMCs to HIV-1 In-
fection.
 
To examine the susceptibility of New World
monkey cells to HIV-1 infection, PBMCs from squirrel
monkeys (SS) and common marmosets (CJ) were inocu-
lated with the NL4–3 virus, a CXCR4-using HIV-1 iso-
late. Anticipating that the SS and CJ receptors might not
optimally support HIV-1 entry, the PBMCs from these
New World primates were also incubated with NL4–3
(VSV G), which is an NL4–3 virus transiently pseudotyped
with the VSV G glycoprotein. The VSV G glycoprotein
has previously been shown to allow HIV-1 to enter New
World monkey cell lines, and is incorporated into the
NL4–3 virions during their production from 293T cells
transfected with an HIV-1 provirus. During the initial
round of infection, the NL4–3 (VSV G) pseudotypes can
bypass the typical requirement of HIV-1 for the CD4
and chemokine receptor proteins. The CD4-positive,
CXCR4-positive human lymphocyte line CEMx174 was
included as a positive control and rhesus macaque PBMCs
were included as a negative control.
CEMx174 cells supported the production of the NL4–3
and NL4–3 (VSV G) viruses, which peaked on the second
day after inoculation (Fig. 1 A, left). The viruses produced
from the CEMx174 cells were able to initiate subsequent
rounds of infection in CEMx174 cells (Fig. 1 A, right). In
parallel experiments, the NL43 NL4–3 (VSV G) virus pro-
duced in 293T cells was incubated with the PBMCs from
two rhesus macaques, an Old World monkey that restricts
Figure 1. HIV-1 virus pro-
duction from New World mon-
key PBMCs. Approximately
100,000 RT cpm of wild-type
NL4–3 HIV-1 strain or the
NL4–3 virus pseudotyped with
the VSV G protein (NL4–3 (G))
were incubated with human
CEMx174 cells as a positive
control and rhesus macaque
(MM) PBMCs as a negative
control (A), PBMCs from three
different squirrel monkey (SS)
donors (B), or PBMCs from
three different common marmo-
set (CJ) donors (C). Cells were
washed at 16 h and RT units
were measured in duplicate cul-
tures at 24-h time points. Virus
production on day 2, which for
the primary monkey cells repre-
sents the peak value, is shown
for each cell type in the bar
graphs on the left. Equivalent
RT units of virus produced from
each culture were added to
CEMx174 target cells to assay
for their infectivity (line graphs
on right). Where no detectable
virus was produced after the
round of initial infection (e.g.,
wild-type NL4–3 infection of
New World monkey PBMCs),
the entire supernatant was
added. Target cells were washed
at 16 h and RT units were mea-
sured at 24-h time points. 
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HIV-1 replication at a post-entry stage. Little or no virus
was produced from the rhesus macaque PBMCs and super-
natants from these Old World monkey cells were not able
to initiate detectable infection of CEMx174 cells (Fig. 1 A).
The SS and CJ PBMCs from three independent donors
did not produce virus after exposure to the NL4–3 virus,
but did produce virus after incubation with the NL4–3
(VSV G) pseudotype (Fig. 1, B and C, left panels). Incuba-
tion of the latter group of PBMC supernatants with
CEMx174 cells demonstrated that the virus produced by
SS and CJ PBMCs was infectious for the CEMx174 cells
(Fig. 1, B and C, right panels). Supernatants from the New
World monkey PBMC that had been exposed to the NL4–3
virus did not initiate infections after incubation with
CEMx174 cells.
Our results indicate that infection of New World mon-
key PBMCs by HIV-1 is inefficient. However, both the
SS and CJ PBMCs were infected by HIV-1 that was
pseudotyped by the VSV G glycoprotein and subsequently
produced infectious HIV-1. Thus, although virus entry
into New World monkey PBMCs appears to be ineffi-
cient, subsequent steps in the HIV-1 life cycle can be suc-
cessfully negotiated in these cells. This is in contrast to Old
World PBMCs, where blocks to HIV-1 replication after
virus entry exist.
 
Squirrel Monkey and Common Marmoset Homologues to
HIV-1 Receptors in Humans.
 
To examine whether the in-
efficient entry of HIV-1 into New World monkey PBMCs
resulted from species-specific properties of the viral recep-
tors, the SS and CJ CD4, CXCR4, and CCR5 proteins
were characterized. The polymerase chain reaction was
used to amplify the cDNA from SS and CJ PBMCs, using
primers specific for the 5
 
 
 
 and 3
 
 
 
 untranslated regions of the
genes. Thus, the amplified products include the complete
coding sequence of the genes, without the introduction of
artifactual changes in these regions by the primers. Se-
quences were verified by cloning from three different CJ
donors and two different SS donors.
The CXCR4 molecules of both New World monkeys
(GenBank/EMBL/DDBJ accession nos. AF452612 and
AF452613) exhibited a high degree of amino acid sequence
identity with human CXCR4 (98.3 and 98.0% sequence
identity for squirrel monkey and common marmoset
CXCR4, respectively). Amino acid differences between
the human and New World monkey CXCR4 molecules
are found in the NH
 
2
 
 terminus and the first and third ex-
tracellular loops (ECL1 and ECL3). Notably, neither of the
New World monkey CXCR4 molecules exhibit the dele-
tions in the NH
 
2
 
 terminus or ECL2 that are found in
mouse CXCR4 molecules.
The CCR5 molecules of the New World monkeys
(GenBank/EMBL/DDBJ accession nos. AF452614 and
AF452615) exhibited a lower overall level of sequence sim-
ilarity to their human counterparts than was observed for
the CXCR4 molecules. The SS and CJ CCR5 proteins
exhibited 89.5 and 91.5% sequence identity, respectively,
to human CCR5. Many of the amino acid differences be-
tween the New World monkey CCR5 molecules and hu-
man CCR5 involve the NH
 
2
 
 terminus and extracellular
loops. Both SS and CJ CCR5 proteins exhibit NH
 
2
 
 ter-
mini in which glycine–proline replaces the tyrosine–threo-
nine at residues 15 and 16. This difference may be impor-
tant, as tyrosine 15 is sulfated and contributes to HIV-1
binding and entry (63–65). Both New World monkey
CCR5 proteins have differences in ECL2 and ECL3 se-
quences from human CCR5, although the CJ sequences
are more similar to the human sequences than the SS se-
quences are.
Of the three receptors, the New World monkey CD4
molecules diverge the most from their human counterpart,
displaying 80.3 and 81% sequence identity to human CD4
for the SS and CJ molecules, respectively. An alignment of
the SS and CJ CD4 sequence to the human and rhesus
monkey proteins, which support HIV-1 infection, and to
murine CD4, which does not support HIV-1 infection, is
shown in Fig. 2 A. Of the four immunoglobulin-like ex-
tracellular domains of CD4, the NH
 
2
 
-terminal domain is
the most important for HIV-1 binding and entry. Phenyl-
alanine 43 and arginine 59 of human CD4 make particu-
larly important contacts with the HIV-1 gp120 glycopro-
tein (66–68). Both SS and CJ CD4 glycoproteins possess a
phenylalanine residue at position 43, but exhibit numerous
differences from human CD4 in the adjacent regions of
the protein. For example, the CJ CD4 has a glutamine at
residue 59.
 
Permissivity of New World Monkey Chemokine Receptors
for HIV-1 Entry.
 
The SS and CJ CXCR4 and CCR5
cDNAs were expressed transiently in Cf2Th canine thy-
mocytes, which are permissive for HIV-1 or SIV infection
only after complementation with appropriate CD4 and
chemokine receptor proteins (69). Cf2Th cells transfected
with the SS and CJ CXCR4-expressing plasmids stained
with two conformation-dependent CXCR4-reactive mono-
clonal antibodies, 12G5 and 44717.111 (Table I). In trans-
fected Cf2Th cells, human and New World monkey
CCR5 proteins were recognized comparably by 3A9, an
antibody that binds a linear, NH
 
2
 
-terminal CCR5 epitope,
and by 2D7, a conformation-dependent antibody directed
against the CCR5 ECL 2 (Table I).
To determine the ability of the New World monkey
chemokine receptors to support HIV-1 infection, Cf2Th
canine thymocytes transiently expressing human CD4 and
either human, SS or CJ chemokine receptors were exposed
to recombinant HIV-1 bearing different HIV-1 envelope
glycoproteins. The ability of the SS and CJ CXCR4 and
CCR5 proteins to allow HIV-1 infection, relative to that
of the human receptors, was assessed by monitoring the
expression of EGFP, which is encoded by the recombinant
virus, in the target cells. Fig. 3 A shows that the squirrel
monkey and common marmoset CXCR4 molecules
support the entry of viruses bearing several X4 or R5X4
HIV-1 envelope glycoproteins, with an efficiency roughly
50% of that seen for human CXCR4. The different infec-
tion efficiencies associated with cells expressing human 
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CXCR4 may relate to intrinsic differences in the efficien-
cies of the particular HIV-1 envelope glycoproteins and/or
factors associated with individual preparations of each of
the viral stocks.
Cf2Th cells expressing comparable levels of human CD4
and either human, SS, or CJ CCR5 were exposed to re-
combinant HIV-1 bearing the envelope glycoproteins of
three primary R5 isolates (Fig. 3 B). Relative to the EGFP
expression observed in target cells expressing human CD4
and CCR5, the levels of expression seen in cells expressing
the SS or CJ CCR5 proteins were very low. Low but de-
tectable EGFP expression was observed in the latter cells
exposed to the viruses with the JR-FL or YU2 envelope
glycoproteins. For both CXCR4 and CCR5 infection as-
says, Cf2Th cells expressing only human CD4 were used as
negative controls and exhibited undetectable EGFP expres-
sion after exposure to the recombinant HIV-1 bearing the
various HIV-1 envelope glycoproteins (data not shown).
High levels of EGFP expression were observed in all target
cells exposed to recombinant HIV-1 pseudotyped with the
VSV G glycoprotein (data not shown).
These data suggest that the New World monkey
CXCR4 molecules can act as functional receptors for
HIV-1, in conjunction with human CD4. By contrast, the
squirrel monkey and common marmoset CCR5 molecules
are relatively inefficient receptors for R5 HIV-1 isolates in
this setting.
 
Permissivity of New World Monkey CD4 Molecules for HIV-1
Entry.
 
Cf2Th canine thymocytes were transfected with
plasmids expressing human, SS, or CJ CD4 proteins. The
transfected cells were stained with three anti-CD4 mono-
clonal antibodies that recognize different CD4 regions.
Human and New World monkey CD4 molecules were
both efficiently recognized by the Q4120 and CD4v4
monoclonal antibodies, but the New World CD4 proteins
were not recognized by the OKT4A antibody (Table I).
OKT4A recognizes an epitope in domain 1 of CD4 that is
near the HIV-1 gp120 binding site (70).
To compare the functionality of human and New World
monkey CD4 molecules in supporting HIV-1 entry,
Cf2Th cells expressing either human or New World mon-
key CD4 in combination with human or New World
monkey CXCR4 were exposed to recombinant HIV-1
expressing EGFP, as described above. As was observed pre-
viously, cells expressing human CD4 and either SS or CJ
CXCR4 proteins supported HIV-1 entry at roughly 50%
the level seen for cells expressing human CD4 and human
CXCR4 molecules (Fig. 4, A and B). Cells expressing ei-
Figure 2. Predicted amino
acid alignment of Ig domains 1
and 2 of New World monkey
CD4 proteins. PCR primers
specific for the 5  and 3  un-
translated regions were used to
amplify CD4 from cDNA gen-
erated from squirrel monkey or
marmoset PBMCs. (A) The pre-
dicted amino acid sequences of
these cloned CD4 molecules are
aligned to the previously identi-
fied sequences of human, rhesus
macaque, and murine CD4. The
shaded boxes designate Ig do-
mains 1 and 2. The solid line
identifies the signal sequence, which is cleaved
from the mature protein. Dots (.) denote residues
identical to the human sequence and minus signs
( ) denote deletions. Gray arrows denote residues
that differ from the published squirrel monkey
CD4 allele D86588. GenBank/EMBL/DDBJ ac-
cession nos. for the sequences are as follows: hu-
man, M12807; rhesus, D63347; squirrel monkey,
AF452617; common marmoset, AF452616;
mouse, NM_013488. (B) The region of human
CD4 that makes important contacts with the HIV-1
gp120 glycoprotein is aligned with the analogous
region of squirrel monkey and common marmoset
CD4 proteins. Phenylalanine 43 and arginine 59
(arrows) are particularly important residues for
gp120 binding (references 45, 77, and 79).
Changes introduced into the squirrel monkey and
common marmoset CD4 molecules in this study
are shown in bold. 
437
 
LaBonte et al.
 
ther SS or CJ CD4 did not support efficient infection re-
gardless of the coexpression of human or New World
monkey CXCR4 molecules. A small percentage of EGFP-
positive cells was observed after infection of the cells ex-
pressing both marmoset receptors exposed to the recombi-
nant KB9 virus (Fig. 4 B). This was consistently higher
than the background associated with cells transfected only
with the human CD4-expressing plasmid. Recombinant
HIV-1 pseudotyped with the VSV G glycoprotein infected
all of the cells efficiently (data not shown). These results in-
dicate that the New World monkey CD4 molecules are
not efficient HIV-1 receptors.
Studies similar to those described above were performed
with cells transiently expressing human or New World
 
Table I.
 
Antibody Recognition of HIV-1 Receptors from New World Monkeys
 
12G5 44717.111 3A9 2D7 Q4120 CD4v4 OKT4A
H CXCR4
 
  
 
SS CXCR4
 
  
CJ CXCR4   
H CCR5   
SS CCR5   
CJ CCR5   
H CD4     
SS CD4     
SS CD4 Y42S     
SS CD4 Q48P     
SS CD4 Y42S/Q48P     
SS CD4 R33Q     
SS CD4 R33Q/Y42S     
SS CD4 R33Q/Q48P     
SS CD4 R33Q/Y42S/Q48P     
CJ CD4     
CJ CD4 Q59R     
CJ CD4 Q48P     
CJ CD4 Q48P/Q59R     
H, human; SS, squirrel monkey; CJ, common marmoset.
Figure 3. Ability of New World monkey chemokine receptors to
support HIV-1 entry. Cf2Th cells were cotransfected with (A) human
CD4 and human, squirrel monkey, or common marmoset CXCR4, or
(B) human CD4 and human, squirrel monkey, or common marmoset
CCR5. Recombinant HIV-1 containing the indicated HIV-1 envelope
glycoproteins and encoding EGFP was incubated with the cells. 48 h
later, EGFP-positive cells were scored. To control for variation in trans-
fection efficiency, the values shown were normalized based on CD4 ex-
pression levels determined by Q4120 antibody staining of cell cultures
plated in parallel. The entry levels observed in cells expressing human
CXCR4 (A) or CCR5 (B) were used as a baseline and all other entry val-
ues were multiplied by the percent that their associated CD4 expression
level differed from the CD4 expression levels of the reference cells. In the
cases where little or no infection was seen, the value is indicated numerically.438 Receptor Blocks to HIV-1 Entry in New World Monkey Cells
monkey CD4 and CCR5 molecules. The results in Fig. 5
confirm that neither New World monkey CD4 nor CCR5
efficiently support the entry of viruses with R5 HIV-1 en-
velope glycoproteins.
In the studies described above, low but reproducible lev-
els of HIV-1 entry occurred in cells expressing the CD4
and CXCR4 receptors from common marmosets. To ver-
ify this observation, Cf2Th lines stably expressing both
CD4 and CXCR4 derived from humans, squirrel mon-
keys, and common marmosets were established. Fig. 6
shows that these cell lines stain with the CD4-specific anti-
body Q4120 and the CXCR4-specific antibody 12G5;
staining with the CCR5-specific antibody 2D7 was equiv-
alent to that seen with an irrelevant antibody (data not
shown). Recombinant HIV-1 containing either CXCR4-
using HIV-1 envelope glycoproteins or the VSV G glyco-
protein were incubated with the Cf2Th cell lines express-
ing human, squirrel monkey, or common marmoset CD4
and CXCR4 glycoproteins. 48 h later, EGFP-positive cells
were visualized (Fig. 7). Viruses with the HIV-1 envelope
glycoproteins efficiently infected the cell line expressing the
human receptors, and viruses with the VSV G glycoprotein
infected all three cell lines efficiently. Cells expressing the
squirrel monkey receptors were almost completely resistant
to infection by viruses with the HIV-1 envelope glycopro-
teins. Some of these viruses, however, were able to infect
the cells expressing common marmoset receptors at a low
level. These results suggest that the CD4 and CXCR4
molecules of common marmosets can support the entry of
HIV-1 with some X4 or R5X4 envelope glycoproteins, al-
though these New World monkey receptors are much less
efficient than their human homologues.
HIV-1 gp120 Binding to Wild-Type and Variant New
World Monkey CD4 Molecules. The studies described above
indicate that New World monkey CD4 molecules rep-
resent a major block to HIV-1 infection of these spe-
cies. Based on the alignment of the human and New
World monkey CD4 sequences and the known x-ray
crystal structure of the HIV-1 gp120-human CD4 com-
plex, amino acid residues in the monkey CD4 sequences
that could potentially decrease gp120-CD4 binding affin-
Figure 4. Ability of New World monkey CD4 to support entry of
CXCR4-using HIV-1. Cf2Th cells were cotransfected with human CD4
and either human or New World monkey CXCR4, or with New World
monkey CD4 and either human or New World monkey CXCR4. Re-
combinant, EGFP-expressing HIV-1 bearing the indicated CXCR4-
using HIV-1 envelope glycoproteins was incubated with the cells, and
EGFP-positive cells were scored as described in the Fig. 3 legend. Human
receptors were compared with those of squirrel monkeys (A) or common
marmosets (B).
Figure 5. Ability of New World monkey CD4 to support entry of
CCR5-using HIV-1. Cf2Th cells were cotransfected with human CD4
and either human or New World monkey CCR5, or with New World
monkey CD4 and either human or New World monkey CCR5. Re-
combinant, EGFP-expressing HIV-1 bearing the indicated CCR5-using
HIV-1 envelope glycoproteins was incubated with the cells, and EGFP-
positive cells were scored as described in the Fig. 3 legend. Human recep-
tors were compared with those of squirrel monkeys (A) or common mar-
mosets (B).439 LaBonte et al.
ity were identified. HIV-1 gp120 primarily contacts the
CDR2-like loop of CD4, spanning CD4 residues 40–61,
with CD4 residues phenylalanine 43 and arginine 59 play-
ing critical roles in the interaction (66–68). Squirrel mon-
key CD4 retains phenylalanine 43 and arginine 59, but has
a bulky tyrosine replacing the serine 42 found in human
CD4. Moreover, a glutamine replaces the proline 48 in
human CD4, a substitution that could alter the turn struc-
ture in the CD4 CDR2 loop (Fig. 2 B). Common mar-
moset CD4 also has a glutamine at residue 48, but in addi-
tion has a glutamine replacing the critical arginine 59
found in human CD4. To investigate the functional sig-
nificance of these sequence differences, variants of the
squirrel monkey and common marmoset CD4 molecules
were created in which these identified residues were indi-
vidually or in combination altered to the amino acid
found in human CD4 (Fig. 2 B). The mutant CD4 pro-
teins were efficiently expressed on the surface of trans-
fected 293T cells, as judged by staining with the anti-CD4
monoclonal antibodies Q4120 and CD4v4 (Table I). The
OKT4A antibody, which recognizes a CDR2 loop
epitope in domain 1 of CD4, did not bind any of the mu-
tant SS and CJ CD4 molecules.
The ability of the gp120 envelope glycoprotein from the
ADA, JR-FL, and YU2 HIV-1 strains to bind 293T cells
expressing the wild-type and variant New World monkey
CD4 proteins was tested. The HIV-1 gp120 glycoproteins
bound cells expressing human CD4 more efficiently than
cells expressing common marmoset CD4 (Fig. 8). Approx-
imate differences of 20-fold and 100-fold in affinity for the
two CD4 molecules were observed for the ADA and JR-
FL gp120 glycoproteins, respectively. A smaller difference
in affinity was observed for the YU2 gp120 glycoprotein;
the YU2 gp120 bound the CJ CD4 with an apparent Kd of
 100 nM, a significantly higher affinity than was seen for
the ADA or JR-FL gp120 glycoproteins. Thus, the gp120
glycoproteins from different HIV-1 strains apparently bind
the CJ CD4 with a range of affinities. The CJ CD4 mu-
tants Q48P and Q59R bound the gp120 glycoproteins of
all three HIV-1 strains with an affinity that was better than
that associated with the wild-type CJ CD4 protein. The
double mutant CJ CD4 Q48P/Q59R bound the gp120
glycoproteins comparably to the human CD4 protein.
Thus, the differences between the abilities of common
marmoset and human CD4 to bind HIV-1 gp120 can be
largely attributed to species-specific differences in CD4 res-
idues 48 and 59.
In contrast to the results obtained with the CJ CD4, the
squirrel monkey CD4 exhibited no detectable binding to
any of the three gp120 glycoproteins (Fig. 8). The SS CD4
mutants also failed to bind the gp120 glycoproteins (data
not shown). It appears that one or more amino acid differ-
ences between human and squirrel monkey CD4 other
than those affecting residues 42 or 48 result in a major ab-
rogation of gp120-binding ability.
Ability of Mutant New World Monkey CD4 Molecules to
Support HIV-1 Infection. We wished to examine whether
the alterations in glutamine 48 and glutamine 59 of com-
mon marmoset CD4 that restored gp120 binding would
also allow more efficient function as an HIV-1 receptor.
Cf2Th cells transiently expressing human CD4 or CJ CD4
variants along with human CCR5 were incubated with re-
combinant HIV-1 bearing the ADA, JR-FL, or YU2 HIV-1
envelope glycoproteins. Measurement of EGFP in the
target cells revealed that, as expected, cells expressing hu-
man CD4 allowed more efficient infection than cells ex-
pressing the wild-type CJ CD4 molecule (Fig. 9, top
panel). Compared with cells expressing the wild-type CJ
CD4 protein, cells expressing the Q48P and Q59R variants
supported more efficient virus infection. Cells expressing
the double mutant (CJ CD4 Q48P/Q59R) were infected
with efficiencies ranging from 50–80 percent of that seen
for cells expressing human CD4.
To examine the ability of the mutant CJ CD4 proteins
to serve as receptor for CXCR4-using HIV-1, Cf2Th cells
transiently expressing human CD4 or CJ CD4 variants
along with human CXCR4 were incubated with recombi-
nant HIV-1 bearing the envelope glycoproteins of the
HXBc2, 3.2, KB9, MN, or MCGP HIV-1 strains. The ob-
served EGFP levels in the target cells corroborated the re-
sults presented in Fig. 9 (data not shown). For each recom-
Figure 6. CD4 and CXCR4 expression levels in stable Cf2Th cell
lines. Cf2Th cells stably expressing CD4 and CXCR4 of the indicated
species were stained with Q4120 antibody (for CD4) and 12G5 antibody
(for CXCR4). The 2D7 anti-CCR5 antibody was used as a negative
control (shaded peak).440 Receptor Blocks to HIV-1 Entry in New World Monkey Cells
binant virus, the level of infection observed was lowest in
cells expressing wild-type CJ CD4 and progressively higher
in the cells expressing CJ CD4 Q48P, CJ CD4 Q59R, CJ
CD4 Q48P/Q59R, and human CD4.
In assays similar to those described above, the wild-type
squirrel monkey CD4 and its mutant derivatives were co-
expressed with human CCR5 in Cf2Th cells. The cells
were incubated with recombinant HIV-1 containing the
envelope glycoproteins of CCR5-using HIV-1 isolates. No
EGFP expression was detected in these cells (Fig. 9, middle
panel), indicating that the squirrel monkey CD4 and mu-
tant derivatives were unable to support HIV-1 entry. Thus,
as was deduced from the gp120 binding assays, differences
between human, and squirrel monkey CD4 other than
those at residues 42 or 48 account for the poor function of
the latter molecule as an HIV-1 receptor. Fig. 2 A shows
that the squirrel monkey CD4 allele that we cloned differs
from a published squirrel monkey allele in three amino ac-
Figure 7. Infection of cells stably expressing CD4 and CXCR4 of different species. Recombinant, EGFP-expressing HIV-1 bearing the indicated en-
velope glycoproteins were incubated with Cf2Th cells stably expressing CD4 and CXCR4 molecules of the indicated species. EGFP-positive cells are
shown and were quantified by flow cytometry, with the percentage of EGFP-positive cells indicated in the corner of each panel.441 LaBonte et al.
ids. However, in our cloned allele, two of these residues,
alanine 22 in the signal sequence and arginine 59, are iden-
tical to those found in human CD4. At the third residue
(residue 33), our SS CD4 clone differed from all known
CD4 sequences by virtue of an arginine in place of
glutamine. To test if this substitution accounted for the
poor functionality of SS CD4 as an HIV-1 receptor, argi-
nine 33 was converted to glutamine in the context of the
wild-type and mutant SS CD4 proteins (Fig. 2 B). All of
these molecules were expressed efficiently on the cell sur-
face and were recognized by the Q4120 and CD4v4 anti-
bodies, but were not recognized by OKT4A (Table I). The
SS CD4 variants were coexpressed with human CCR5 in
Cf2Th cells, which were incubated with recombinant
HIV-1 EGFP-reporter virus containing CCR5-using en-
velope glycoproteins. The conversion of arginine 33 to
glutamine, in either wild-type or mutant SS CD4 contexts,
did not restore functional HIV-1 receptor activity (Fig. 9,
bottom panel).
Discussion
Our results indicate that the major restriction limiting
HIV-1 infection of New World monkey cells operates at
the level of virus entry. The inefficiency with which squir-
rel monkey and common marmoset CD4 molecules sup-
port HIV-1 binding and entry creates a significant hurdle
for all strains of HIV-1 to replicate in cells of these species.
In addition, New World monkey CCR5 proteins are inef-
ficient receptors for HIV-1. As most naturally transmitted
Figure 8. Binding of soluble gp120 glyco-
protein to New World monkey CD4 mole-
cules. 293T cells were transfected with plas-
mids encoding human, marmoset (CJ), or
mutant marmoset CD4 molecules and assayed
for binding to soluble purified gp120 by flow
cytometry. The concentration of the gp120
envelope glycoprotein used in the assay is
shown on the x-axis, and the mean fluores-
cence associated with detection of bound
gp120 is on the y-axis. SS CD4 showed no
binding to gp120 molecules at any concentra-
tion and was used as a negative control.442 Receptor Blocks to HIV-1 Entry in New World Monkey Cells
primate lentiviruses utilize CD4 and CCR5 as receptors,
the species-specific polymorphisms in these molecules
would be sufficient to limit natural infection of New
World monkeys, even if they were exposed to these agents.
Of the HIV-1 receptors, New World monkey CD4 exhib-
its the greatest degree of sequence divergence from human
CD4. Two differences involving CD4 residues 48 and 59
explain, to a large extent, the inability of the CD4 glyco-
protein of common marmosets to support HIV-1 binding
and entry. In human CD4, proline 48 contributes to a
 -turn that results in the antiparallel orientation of the C  
and D strands of the protein, each of which makes impor-
tant contacts with HIV-1 gp120 (66, 68). The C   strand
includes phenylalanine 43, which fills a receptor-binding
pocket on gp120 and the D strand includes arginine 59,
which forms a salt bridge with gp120 aspartic acid 368 (66).
The glutamine at position 59 of common marmoset CD4
would be unable to form such a favorable bond. The re-
sulting decreases in the affinity of the HIV-1 gp120-CD4
interaction apparently explain the poor receptor function
of the marmoset protein.
The squirrel monkey CD4 did not detectably bind or
support infection of HIV-1, although it was efficiently ex-
pressed on the surface of target cells. The basis for this poor
activity as an HIV-1 receptor requires further investigation.
Our studies indicate that sequences present in squirrel
monkey CD4 other than arginine 33, tyrosine 42, and pro-
line 48 prevent this molecule from acting as a functional re-
ceptor molecule for HIV-1. Future studies changing other
nonhomologous amino acid residues to their human coun-
terparts should be able to identify the determinants of SS
CD4 that restrict its usage as an HIV-1 receptor.
The New World monkey chemokine receptors exhibit
less sequence divergence from their human counterparts
than does CD4. The CXCR4 proteins of these monkeys
are most conserved among the three molecules, and also
exhibit the highest levels of HIV-1 receptor activity. This is
consistent with the reported ability of some R5X4 and X4
HIV-1 strains to utilize CXCR4 molecules from evolu-
tionarily distant mammalian species, including rodents.
New World monkey CCR5 exhibited very poor corecep-
tor function for HIV-1 infection. Differences in the NH2
terminus, including a glycine replacing a critical sulfated ty-
rosine at residue 15 of human CCR5, probably contribute
to the functional coreceptor differences between New
World monkey and human CCR5 proteins.
Our results indicate that HIV-1 can effectively negotiate
all the steps in the viral life cycle following virus entry in
New World monkey cells. The early, post-entry block to
HIV-1 infection seen in Old World monkeys does not ap-
pear to be operative in New World monkeys. Cellular co-
factors in New World monkey cells must be able to inter-
act functionally with the HIV-1 Tat, Rev, and Vif proteins
to allow successful completion of the late phase of virus
replication (71–74). Likewise, New World monkey HP68
and cyclophilin A are apparently compatible with HIV-1
Gag components to allow capsid formation and the attain-
ment of virion infectivity, respectively (75–78).
The discrete nature of the replication blocks to HIV-1 in
New World monkeys raise the possibility that these hurdles
might be bypassed by directed adaptation of the virus. Our
results suggest that such attempts might be more successful
with common marmosets than squirrel monkeys. Common
marmosets would be attractive hosts in an animal model of
HIV-1 infection, as they are small, relatively inexpensive,
and easy to breed (79). Common marmosets exhibit spe-
cies-wide homogenization of their major histocompatibil-
ity loci and a high incidence of multiple births, facilitating
Figure 9. Effect of amino acid changes on the receptor activity of
common marmoset (CJ) CD4 or squirrel monkey (SS) CD4. Cf2Th cells
were transfected with plasmids encoding human CCR5 and the wild-
type common marmoset (CJ) or squirrel monkey (SS) CD4 proteins, or
the indicated mutant CD4 proteins. The cells were then incubated with
recombinant, EGFP-expressing HIV-1 bearing the ADA, JR-FL, or YU2
envelope glycoproteins. After 48 h, cells were assayed for EGFP expression,
as described in the Fig. 3 legend.443 LaBonte et al.
transplants and adoptive transfer experiments between sib-
lings (80). The peripheral blood lymphocytes of common
marmosets can be readily transformed by Herpes saimiri or
ateles and are easily propagated in recombinant human IL-2
(81). These features make common marmosets ideal for
studying interactions of the virus with the immune system.
Future studies will explore the possibilities of establishing
such a model.
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